Allakos Past Earnings Performance
Past criteria checks 0/6
Allakos's earnings have been declining at an average annual rate of -24.9%, while the Biotechs industry saw earnings growing at 17.7% annually.
Key information
-24.9%
Earnings growth rate
-13.6%
EPS growth rate
Biotechs Industry Growth | -14.6% |
Revenue growth rate | n/a |
Return on equity | -110.0% |
Net Margin | n/a |
Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
No updates
Recent updates
Revenue & Expenses BreakdownBeta
How Allakos makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
31 Dec 23 | 0 | -186 | 45 | 151 |
30 Sep 23 | 0 | -166 | 50 | 140 |
30 Jun 23 | 0 | -151 | 46 | 114 |
31 Mar 23 | 0 | -165 | 50 | 121 |
31 Dec 22 | 0 | -320 | 57 | 265 |
30 Sep 22 | 0 | -371 | 65 | 298 |
30 Jun 22 | 0 | -403 | 76 | 328 |
31 Mar 22 | 0 | -411 | 77 | 334 |
31 Dec 21 | 0 | -270 | 75 | 196 |
30 Sep 21 | 0 | -220 | 68 | 152 |
30 Jun 21 | 0 | -199 | 61 | 139 |
31 Mar 21 | 0 | -181 | 57 | 126 |
31 Dec 20 | 0 | -153 | 52 | 106 |
30 Sep 20 | 0 | -134 | 46 | 94 |
30 Jun 20 | 0 | -113 | 41 | 79 |
31 Mar 20 | 0 | -93 | 35 | 65 |
31 Dec 19 | 0 | -85 | 30 | 62 |
30 Sep 19 | 0 | -75 | 24 | 56 |
30 Jun 19 | 0 | -65 | 20 | 49 |
31 Mar 19 | 0 | -55 | 16 | 42 |
31 Dec 18 | 0 | -44 | 12 | 33 |
30 Sep 18 | 0 | -37 | 9 | 27 |
30 Jun 18 | 0 | -32 | 7 | 24 |
31 Mar 18 | 0 | -27 | 5 | 21 |
31 Dec 17 | 0 | -24 | 4 | 19 |
Quality Earnings: 37Z is currently unprofitable.
Growing Profit Margin: 37Z is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 37Z is unprofitable, and losses have increased over the past 5 years at a rate of 24.9% per year.
Accelerating Growth: Unable to compare 37Z's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 37Z is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-2.9%).
Return on Equity
High ROE: 37Z has a negative Return on Equity (-110%), as it is currently unprofitable.